JNJ-38877618 is an inhibitor of methionine adenosyltransferase 2 (MAT2A) that is being investigated for cancer treatment, particularly cancers associated with MTAP (Methylthioadenosine Phosphorylase) gene mutations. This compound has potential to inhibit cancer cell growth by disrupting methylation processes and polyamine synthesis, which are crucial for cancer cell division and growth. Currently, JNJ-38877618 is in the research and clinical trial stages to evaluate its efficacy and safety for use as a cancer treatment in humans.